Literature DB >> 20383031

Effects of rolipram on U46619-induced contraction and cyclic nucleotide content in the porcine coronary artery.

Takeharu Kaneda1, Takashi Kubota, Kenji Fujimoto, Norimoto Urakawa, Shinjiro Nakajyo, Kazumasa Shimizu.   

Abstract

The effects of various selective phosphodiesterase (PDE) inhibitors on muscle contractility and cyclic nucleotide content in the porcine coronary artery were investigated. Various selective PDE inhibitors, vinpocetine (type 1), erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA, type 2), milrinone (type 3), rolipram (type 4), Ro20-1724 (type 4), and zaprinast (type 5), inhibited U46619-induced contractions in a concentration-dependent manner. The rank order of potency for the porcine coronary artery was rolipram > Ro20-1724 >milrinone > vinpocetine > zaprinast > EHNA, which was different from that of both the porcine carotid artery and aorta. Rolipram inhibited the U46619-induced muscle tension with a decreased [Ca(2+)](i) level, but inhibited the high K(+)-induced contraction without a change in [Ca(2+)](i) level. Rolipram increased cAMP but not cGMP content. Iberiotoxin restored the inhibition of muscle tension and the [Ca(2+)](i) levels induced by rolipram. U46619 and caffeine induced a transient increase in the [Ca(2+)](i) levels in a Ca(2+)-free solution, but rolipram only inhibited the U46619-induced Ca(2+) transient. In conclusion, rolipram is the most potent inhibitor in the porcine coronary artery, but not in the carotid artery and aorta. Moreover it is suggested that the mechanism by which rolipram causes relaxation is due to a decrease in the [Ca(2+)](i) levels and of the Ca(2+) sensitivity of the contractile elements to cAMP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20383031     DOI: 10.1540/jsmr.46.17

Source DB:  PubMed          Journal:  J Smooth Muscle Res        ISSN: 0916-8737


  1 in total

1.  Imidazole-induced contractions in bovine tracheal smooth muscle are not dependent on the cAMP pathway.

Authors:  Takeharu Kaneda; Hidenori Kanda; Tsuyoshi Tajima; Norimoto Urakawa; Kazumasa Shimizu
Journal:  J Vet Med Sci       Date:  2017-12-18       Impact factor: 1.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.